Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report

Limited strategies are available at disease progression on osimertinib for patients with EGFR-mutant NSCLC. The emergence of the on-target EGFR C797S mutation has been described as one of the most common mechanisms of resistance. In addition, loss of the EGFR T790M mutation has been mainly investiga...

Descripción completa

Detalles Bibliográficos
Autores principales: Enrico, Diego, Tsou, Florencia, Catani, Greta, Pupareli, Carmen, Girotti, María Romina, Ulloa Alvarez, David Esteban, Waisberg, Federico, Rodríguez, Andrés, Reyes, Roxana, Chacón, Matías, Reguart, Noemí, Martín, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926104/
https://www.ncbi.nlm.nih.gov/pubmed/36798785
http://dx.doi.org/10.1016/j.jtocrr.2022.100456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926104/
https://www.ncbi.nlm.nih.gov/pubmed/36798785
http://dx.doi.org/10.1016/j.jtocrr.2022.100456

Ejemplares similares